Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 7/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | RECQL | P46063 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | CDK2 | P24941 | 4/20 | 0.48 |
| ▸ | SLCO2B1 | O94956 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | APEX1 | P27695 | 3/20 | 0.48 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8934619 | 0.70 | MEN1 (0.47) | BCL9CTNNB1MEN1KMT2AKDM4E | |
| SCHEMBL4637442 | 0.70 | POLB (0.51) | MEN1KMT2AKDM4EMAPTCYP3A4 | |
| SCHEMBL31022147 | 0.70 | AMY1A (0.81) | BCL9CTNNB1MEN1KMT2AKDM4E | |
| SCHEMBL222227 | 0.69 | CDK5 (0.53) | MEN1KMT2AKDM4EALOX15MAPT | |
| SCHEMBL29574854 | 0.69 | MEN1 (0.42) | MEN1KMT2AKDM4EALOX15MAPT | |
| SCHEMBL31722840 | 0.67 | MEN1 (0.59) | BCL9CTNNB1MEN1KMT2AKDM4E | |
| SCHEMBL10037939 | 0.67 | MEN1 (0.76) | BCL9CTNNB1MEN1KMT2AKDM4E | |
| SCHEMBL4879748 | 0.67 | AMY1A (0.78) | BCL9CTNNB1MEN1KMT2AKDM4E | |
| SCHEMBL31682973 | 0.66 | TERT (0.76) | BCL9CTNNB1MEN1KMT2AKDM4E | |
| SCHEMBL34972 | 0.66 | TERT (0.76) | BCL9CTNNB1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508183-B1 | Interleukin-1 blocker for use in the treatment of age-related macular degeneration | TEXAS A & M UNIV SYS (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20130059841-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-03-07 | — | — | US | disclosed |
| US-8318741-B2 | Therapeutic compositions and methods | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2508183-A1 | Interleukin-1 blocker for use in the treatment of age-related macular degeneration | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2508182-A1 | Hydralazine for use in the treatment of age-related macular degeneration | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20120196868-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120115959-A1 | Therapeutic Compositions And Methods | THE TEXAS A&M UNIVERSITY SYSTEM | 2012-05-10 | — | — | US | disclosed |
| US-20120071485-A1 | Therapeutic Compositions And Methods | THE TEXAS A&M UNIVERSITY SYSTEM | 2012-03-22 | — | — | US | disclosed |
| US-8088773-B2 | Therapeutic compositions and methods | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-01-03 | — | — | US | disclosed |
| US-20060276458-A1 | Therapeutic compositions and methods | THE TEXAS A & M UNIVERSITY SYSTEM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276458-A1 | Therapeutic compositions and methods | PDE6H, PDE6C, PDE6D | BCL9 1456/4885CTNNB1 1885/4885MEN1 2478/4885 |
| US-20120115959-A1 | Therapeutic Compositions And Methods | PDE6C, PDE6H, PDE6D | BCL9 1248/4885CTNNB1 1742/4885MEN1 3145/4885 |
| US-20120071485-A1 | Therapeutic Compositions And Methods | PDE6H, PDE6C, PDE6D | BCL9 1456/4885CTNNB1 1885/4885MEN1 2478/4885 |
| US-20120196868-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PDE6H, PDE6C, PDE6D | BCL9 1456/4885CTNNB1 1885/4885MEN1 2478/4885 |
| US-20130059841-A1 | THERAPEUTIC COMPOSITIONS AND METHODS | PDE6H, PDE6C, PDE6D | BCL9 1456/4885CTNNB1 1885/4885MEN1 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.